help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lamberts, S. W.
Right arrow Articles by Oosterom, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lamberts, S. W.
Right arrow Articles by Oosterom, R.

Journal of Clinical Endocrinology & Metabolism, Vol 56, 230-233, Copyright © 1983 by Endocrine Society


ARTICLES

Absence of a suppressive effect of 2-hydroxyestrone on hyperprolactinemia in patients with prolactinomas before and after estradiol administration

SW Lamberts and R Oosterom

The effect of the infusion of 2-hydroxyestrone (125 micrograms/h for 8 h) on plasma PRL levels was investigated before and 64 h after the administration of 1 mg estradiol benzoate in five patients with PRL- secreting pituitary adenomas. There was no effect on the circulating PRL levels measured hourly for 8 h during both episodes of 2- hydroxyestrone infusion, but plasma LH and FSH levels were suppressed. Infusion of 2-hydroxyestrone in two hyperprolactinemic patients with craniopharyngeomas also did not change the circulating PRL levels. We conclude that: 1) 2-Hydroxyestrone does not suppress PRL levels in patients with prolactinomas. This is not caused by the low estrogenic state of these patients, because 2-hydroxyestrone remained ineffective after the administration of estradiol. 2-Hydroxyestrone was also not able to suppress the estradiol-induced stimulation of PRL release. 2) 2- Hydroxyestrone does not diminish PRL levels in patients with suprasellar tumors and hyperprolactinemia. Therefore, infusion of 2- hydroxyestrone cannot be used in the differential diagnosis of hypothalamic and tumoral hyperprolactinemia.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1983 by The Endocrine Society